Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Women taking hormonal contraceptives are at highest risk of FSD: Study

Women taking non-oral and oral hormonal contraceptives were at highest risk of Female Sexual Dysfunction, according to a study of female German medical students published today in The Journal of Sexual Medicine. Interestingly, women taking non-hormonal contraceptives were at lowest risk for FSD, more than women not using any contraceptive.

4 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

BioSante Pharmaceuticals, Inc. will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Priligy - new drug for premature ejaculation

For men suffering from premature ejaculation there may be a new savior in town. The new drug called Priligy is reported to triple the time a man can last in bed. It is currently not licensed in the UK, but is available and licensed for use in a number of other European countries.

28 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Ampio Pharmaceuticals, Inc., today announced that it has entered into a letter of intent to acquire DMI Biosciences, Inc.

23 Apr 2010

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.

20 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Premature ejaculation causes intense distress on men and partners

Today, the first key findings from 'PE Confidential', a unique Europe-wide public survey on premature ejaculation (PE), reveal the intense - and in many cases - long years of silent suffering that PE poses on men and their partners. 'PE Confidential' also highlights the significant burden that PE places on couples' relationships and why men are reluctant to seek help, advice and solutions for the condition.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

NexMed expands San Diego facilities to accommodate pre-clinical research services

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has expanded its San Diego facilities to accommodate an increase in demand for its pre-clinical research services.

9 Apr 2010

PSA test distress, study urges caution

A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.

9 Apr 2010

FamilyCord acquires assets of Vista Cord

FamilyCord, a subsidiary of California Cryobank, announced the recent asset acquisition of Vista Cord, a regional cord blood bank primarily servicing the southern US states. In conjunction with the FDA and cryogenic transport experts, FamilyCord has successfully relocated all cord blood units to their state-of-the-art facility in Los Angeles.

6 Apr 2010

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Women taking hormonal contraceptives are at highest risk of FSD: Study

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Priligy - new drug for premature ejaculation

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

Premature ejaculation causes intense distress on men and partners

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Investment report on Rexahn Pharmaceuticals

NexMed expands San Diego facilities to accommodate pre-clinical research services

PSA test distress, study urges caution

FamilyCord acquires assets of Vista Cord

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in